TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of Glycogen synthase kinase-3 betaMore data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 8.40nMAssay Description:Inhibition of recombinant human GSK3beta (636 to 661 residues) assessed as reduction in human muscle glycogen synthase type 1 fragment phosphorylatio...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 8.40nMAssay Description:Inhibition of recombinant human GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate measured after 60 mins by ADP-Glo luminescence assayMore data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of GSK3beta (unknown origin)More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of GSK3beta (unknown origin) pre-incubated for 30 mins followed by ULight-GS (Ser641/pSer657) peptide substrate addition and measured afte...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of GSK3beta (unknown origin) pre-incubated for 30 mins followed by ULight-GS (Ser641/pSer657) peptide substrate addition and measured afte...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of GSK3beta (unknown origin) pre-incubated for 30 mins followed by ULight-GS (Ser641/pSer657) peptide substrate addition and measured afte...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of recombinant human N-terminal His6-tagged GSK-3beta H350L mutant expressed in baculovirus infected Sf21 cells using GSM as substrate inc...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of recombinant human N-terminal His6-tagged GSK3beta H350L mutant expressed in baculovirus infected Sf21 cells using prephosphorylated pol...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 29nMAssay Description:Inhibition of human recombinant N-terminal His-tagged GSK3beta expressed in Escherichia coli using RRRPASVPPSPSLS RHS(pS)HQRR as substrate incubated ...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 34nMAssay Description:Inhibition of GSK3-beta (unknown origin)More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 34nMAssay Description:Inhibition of GSK3beta (unknown origin)More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 34nMAssay Description:Inhibition of human GSK3betaMore data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 34nMAssay Description:Inhibition of GSK3beta (unknown origin) expressed in Sf9 cells using GS1 as substrate and [gamma32]ATP after 30 min by scinitllation countingMore data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 34nMAssay Description:Inhibition of GSK3beta (unknown origin)More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 48nMAssay Description:Inhibition of human recombinant GSK3-betaMore data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 50nMAssay Description:Inhibition of human GSK3-beta by scintillation countingMore data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 89nMAssay Description:Competitive inhibition of human recombinant full length GSK3beta using YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE as substrate preincubated with enzyme for 10 min...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 92nMAssay Description:Inhibition of GSK3beta after 30 mins by luminescence assayMore data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataEC50: 200nMAssay Description:Effective concentration of compound against glycogen synthase kinase-3 in HEK293 cellsMore data for this Ligand-Target Pair